Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells

Bone

Volumn 41, Issue 4, 2007, Pages 592-602

  Mohamed, Saad Gad Kamel ^a   Sugiyama, Eiji ^a   Shinoda, Kouichiro ^a   Taki, Hirofumi ^a   Hounoki, Hiroyuki ^a   Abdel Aziz, Hekmat Osman ^a   Maruyama, Muneharu ^a   Kobayashi, Masashi ^a   Ogawa, Hirofumi ^a   Miyahara, Tatsuro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

c Fos; c Jun; Interleukin 10; NFATc1; Osteoclastogenesis; RANKL; RAW264.7 cells

Indexed keywords

BETA ACTIN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; INHIBITION KINETICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; HUMANS; INTERLEUKIN-10; MICE; NF-KAPPA B P50 SUBUNIT; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RANK LIGAND; RECEPTORS, INTERLEUKIN-10; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1;

EID: 34548533322     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.05.016     Document Type: Article

References (50)

1. Roodman G.D. Advances in bone biology: the osteoclast. Endocr. Rev. 17 (1996) 308-332
2. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
3. Ross F.P. RANKing the importance of measles virus in Paget's disease. J. Clin. Invest. 105 (2000) 555-558
4. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
5. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
6. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
7. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., and Teitelbaum S.L. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 (2000) 1481-1488
8. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 (1997) 25190-25194
9. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3597-3602
10. Kobayashi N., Kadono Y., Naito A., Matsumoto K., Yamamoto T., Tanaka S., et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20 (2001) 1271-1280
11. Naito A., Azuma S., Tanaka S., Miyazaki T., Takaki S., Takatsu K., et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4 (1999) 353-362
12. Wong B.R., Josien R., Lee S.Y., Vologodskaia M., Steinman R.M., and Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J. Biol. Chem. 273 (1998) 28355-28359
13. Ishida N., Hayashi K., Hoshijima M., Ogawa T., Koga S., Miyatake Y., et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277 (2002) 41147-41156
14. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3 (2002) 889-901
15. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202 (2005) 1261-1269
16. Ikeda F., Nishimura R., Matsubara T., Tanaka S., Inoue J., Reddy S.V., et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114 (2004) 475-484
17. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279 (2004) 26475-26480
18. 1 cells. J. Immunol. 146 (1991) 3444-3451
19. O'Garra A., Stapleton G., Dhar V., Pearce M., Schumacher J., Rugo H., et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int. Immunol. 2 (1990) 821-832
20. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147 (1991) 3815-3822
21. Sugiyama E., Kuroda A., Taki H., Ikemoto M., Hori T., Yamashita N., et al. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J. Rheumatol. 22 (1995) 2020-2026
22. Hong M.H., Williams H., Jin C.H., and Pike J.W. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J. Bone Miner. Res. 15 (2000) 911-918
23. Joosten L.A., Helsen M.M., Saxne T., Heinegard D., van de Putte L.B., and van den Berg W.B. Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis. Inflamm. Res. 48 (1999) 48-55
24. Owens J.M., Gallagher A.C., and Chambers T.J. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J. Immunol. 157 (1996) 936-940
25. Xu L.X., Kukita T., Kukita A., Otsuka T., Niho Y., and Iijima T. Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J. Cell. Physiol. 165 (1995) 624-629
26. Carmody E.E., Schwarz E.M., Puzas J.E., Rosier R.N., and O'Keefe R.J. Viral interleukin-10 gene inhibition of inflammation, osteoclastogenesis, and bone resorption in response to titanium particles. Arthritis Rheum. 46 (2002) 1298-1308
27. Finbloom D.S., and Winestock K.D. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 α and STAT3 complexes in human T cells and monocytes. J. Immunol. 155 (1995) 1079-1090
28. Ho A.S., Wei S.H., Mui A.L., Miyajima A., and Moore K.W. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol. Cell. Biol. 15 (1995) 5043-5053
29. Wehinger J., Gouilleux F., Groner B., Finke J., Mertelsmann R., and Weber-Nordt R.M. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett. 394 (1996) 365-370
30. Riley J.K., Takeda K., Akira S., and Schreiber R.D. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274 (1999) 16513-16521
31. Driessler F., Venstrom K., Sabat R., Asadullah K., and Schottelius A.J. Molecular mechanisms of interleukin-10-mediated inhibition of NF-κB activity: a role for p50. Clin. Exp. Immunol. 135 (2004) 64-73
32. Schottelius A.J., Mayo M.W., Sartor R.B., and Baldwin Jr. A.S. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J. Biol. Chem. 274 (1999) 31868-31874
33. Wang P., Wu P., Siegel M.I., Egan R.W., and Billah M.M. Interleukin (IL)-10 inhibits nuclear factor κB (NF-κB) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. 270 (1995) 9558-9563
34. Kontoyiannis D., Kotlyarov A., Carballo E., Alexopoulou L., Blackshear P.J., Gaestel M., et al. Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J. 20 (2001) 3760-3770
35. Crawley J.B., Williams L.M., Mander T., Brennan F.M., and Foxwell B.M. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J. Biol. Chem. 271 (1996) 16357-16362
36. Takahashi N., Akatsu T., Udagawa N., Sasaki T., Yamaguchi A., Moseley J.M., et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123 (1988) 2600-2602
37. Zhao C., Irie N., Takada Y., Shimoda K., Miyamoto T., Nishiwaki T., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4 (2006) 111-121
38. Kitamura T., Koshino Y., Shibata F., Oki T., Nakajima H., Nosaka T., et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31 (2003) 1007-1014
39. Kim Y., Sato K., Asagiri M., Morita I., Soma K., and Takayanagi H. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J. Biol. Chem. 280 (2005) 32905-32913
40. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 279 (2004) 45969-45979
41. Evans K.E., and Fox S.W. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol. 8 (2007) 4
42. Bonig H., Korholz D., Pafferath B., Mauz-Korholz C., and Burdach S. Interleukin 10 induced c-fos expression in human B cells by activation of divergent protein kinases. Immunol. Invest. 25 (1996) 115-128
43. Perrin G.Q., Johnson H.M., and Subramaniam P.S. Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the cell cycle. Blood 93 (1999) 208-216
44. Geng Y., Gulbins E., Altman A., and Lotz M. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8602-8606
45. Dokter W.H., Koopmans S.B., and Vellenga E. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-κB) which are involved in IL-6 regulation. Leukemia 10 (1996) 1308-1316
46. Mohamed S.G.K., Sugiyama E., Shinoda K., Hounoki H., Taki H., Maruyama M., et al. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis. Biochem. Biophys. Res. Commun. 329 (2005) 839-845
47. Yang E., Lerner L., Besser D., and Darnell Jr. J.E. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J. Biol. Chem. 278 (2003) 15794-15799
48. Huang H., Chang E.J., Ryu J., Lee Z.H., Lee Y., and Kim H.H. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem. Biophys. Res. Commun. 351 (2006) 99-105
49. Sato K., Suematsu A., Nakashima T., Takemoto-Kimura S., Aoki K., Morishita Y., et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat. Med. 12 (2006) 1410-1416
50. Angel P., Hattori K., Smeal T., and Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55 (1988) 875-885